<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0123-9392</journal-id>
<journal-title><![CDATA[Infectio]]></journal-title>
<abbrev-journal-title><![CDATA[Infect.]]></abbrev-journal-title>
<issn>0123-9392</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Infectología.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0123-93922019000500073</article-id>
<article-id pub-id-type="doi">10.22354/in.v23i1.762</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación y manejo del riesgo cardiovascular en infección por VIH. Consenso de expertos ACIN]]></article-title>
<article-title xml:lang="en"><![CDATA[Evaluation and management of cardiovascualr risk in VIH infection: Expert consensus of ACIN (Colombian Association of Infectious Diseases)]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valderrama Beltrán]]></surname>
<given-names><![CDATA[Sandra Liliana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gualtero]]></surname>
<given-names><![CDATA[Sandra Milena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quiroga]]></surname>
<given-names><![CDATA[Camilo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garzón]]></surname>
<given-names><![CDATA[Javier Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lowenstein de Mendivelson]]></surname>
<given-names><![CDATA[Ellen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tamara]]></surname>
<given-names><![CDATA[Jose Roberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[Angel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castañeda]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cataño]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Botero]]></surname>
<given-names><![CDATA[Claudia Pilar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guevara]]></surname>
<given-names><![CDATA[Freddy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[José Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Oñate]]></surname>
<given-names><![CDATA[José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Posada]]></surname>
<given-names><![CDATA[María Paulina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sussmann]]></surname>
<given-names><![CDATA[Otto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zuluaga De León]]></surname>
<given-names><![CDATA[Iván J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arévalo-Mora]]></surname>
<given-names><![CDATA[Leonardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez Buitrago]]></surname>
<given-names><![CDATA[Ernesto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Pontificia Universidad Javeriana Hospital Universitario San Ignacio ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Pontificia Universidad Javeriana Hospital Universitario San Ignacio Trujillo]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Pontificia Universidad Javeriana Hospital Universitario San Ignacio ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Clínica Colsanitas  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Fundación Caminos IPS Programas integrales de Vital Salud del Caribe IPS ]]></institution>
<addr-line><![CDATA[Barranquilla ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,Clínica Versalles Clínica de La Presentación Unidad de Vacunación del Adulto]]></institution>
<addr-line><![CDATA[Manizales ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,Colsanitas Departamento de Infectología ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Fundación Valle del Lili Infectologia ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Universidad del Valle Centro médico Imbanaco ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="A11">
<institution><![CDATA[,SIES  ]]></institution>
<addr-line><![CDATA[Medellín ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="A12">
<institution><![CDATA[,Asistencia Científica y de Alta Calidad  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="A13">
<institution><![CDATA[,Sociedad de Infectólogos del Caribe Colombiano  ]]></institution>
<addr-line><![CDATA[Barranquilla ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="A14">
<institution><![CDATA[,Centro de Expertos para Atención Integral  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="A15">
<institution><![CDATA[,Universidad del Valle Departamento de Medicina Interna ]]></institution>
<addr-line><![CDATA[Cali ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>23</volume>
<fpage>73</fpage>
<lpage>91</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0123-93922019000500073&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0123-93922019000500073&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0123-93922019000500073&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Los pacientes con infección por VIH tienen una mayor incidencia de eventos cardiovasculares en comparación con la población general; los factores que contribuyen al incremento del riesgo de eventos cardiovasculares son la prevalencia de factores de riesgo cardiovascular tradicionales (FRCV), la infección por VIH que condiciona tanto un proceso de inflamación crónica como alteración de la función endotelial y la exposición a los antirretrovirales. Los factores que deben ser objeto de intervención son los FRCV tradicionales, en especial la alta tasa de fumadores entre este grupo de pacientes, la tamización y tratamiento de HTA, el síndrome metabólico y el acceso temprano a la terapia antirretroviral con medicamentos con mayor perfil de seguridad . Esta guía pretende proveer información y recomendaciones en el ámbito nacional acerca de la relación entre la infección por VIH/SIDA (Síndrome de Inmunodeficiencia Adquirida), uso de antirretrovirales y riesgo cardiovascular.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Patients with VIH infection have greater risk for cardiovascular diseases compared to general population. Risk factors that increase the frequency of cardiovascular events are: presence of cardiovascular traditional risk factors, chronic inflammation by HIV that impairs endothelial function and the exposure to antiretrovirals. The factors that should be the target for intervention are the traditional know cardiovascular factors such, especially high rate of smokers, screening and treatment for hypertension, metabolic syndrome and early access to HAART. The present guidelines provides information about the use of antiretrovirals in patients with HIV and its relation with cardiovascular risk.]]></p></abstract>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Currier]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of antiretroviral treatment - related complications]]></article-title>
<source><![CDATA[Infect Dis Clin]]></source>
<year>2017</year>
<volume>21</volume>
<page-range>103-32</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gordin]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Finley]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dietz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chesson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Vjecha]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Standridge]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CD4+ Count-guided interruption of antiretroviral treatment]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2006</year>
<volume>355</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2283-96</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kitahata]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gange]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Merriman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of early versus deferred antoretroviral therapy for HIV on survival]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2010</year>
<volume>360</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>1815-26</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<collab>The INSIGHT START Study group</collab>
<article-title xml:lang=""><![CDATA[Initiation of antiretroviral therapy in early asymptomatic HIV infection]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>373</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>795-807</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsue]]></surname>
<given-names><![CDATA[PY]]></given-names>
</name>
<name>
<surname><![CDATA[Deeks]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Hunt]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunologic basis of cardiovascular disease in HIV-nifected adults]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2012</year>
<volume>205</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>375-82</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Plutzky]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2012</year>
<volume>205</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>368-74</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schouten]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wit]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[Stolte]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Kootstra]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Der]]></surname>
<given-names><![CDATA[Valk M Van]]></given-names>
</name>
<name>
<surname><![CDATA[Geerlings]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: The AGE h IV cohort study]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2014</year>
<volume>59</volume>
<page-range>1787-97</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>Grupo de expertos del grupo de estudios sobre alteraciones metabólicas de la secretaría del plan nacional sobre sida</collab>
<collab>grupo de estudio de sida</collab>
<article-title xml:lang=""><![CDATA[Documento de consenso sobre alteraciones metabólicas y riesgo cardiovascular en pacientes con infección por el virus de la inmunodeficiencia humana]]></article-title>
<source><![CDATA[Enferm Infecc Microbiol Clin]]></source>
<year>2015</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40.e1-40.e16</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Care]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Panel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Centre]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[August]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Primary care guidelines for the management of HIV/AIDS in British Columbia on behalf of the primary care guidelines panel]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Ministerio de salud gobierno de Chile</collab>
<source><![CDATA[Guía clínica AUGE. Síndrome de inmunodeficiencia humana adquirida VIH/SIDA]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<collab>Ministério de Saúde</collab>
<source><![CDATA[Protocolo clínico e diretrizes terapeuticas para manejo da infecçao pelo HIV em adultos]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Brasília ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lundgren]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Battegay]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Behrens]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De]]></surname>
<given-names><![CDATA[Wit S]]></given-names>
</name>
<name>
<surname><![CDATA[Guaraldi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Katlama]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV]]></article-title>
<source><![CDATA[HIV Med]]></source>
<year>2008</year>
<volume>9</volume>
<page-range>72-81</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stone]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtenstein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Noel]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Merz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lloyd-]]></surname>
<given-names><![CDATA[FDM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults]]></article-title>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Oparil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carter]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Cushman]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Dennison-Himmelfarb]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Handler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2014 Evidence-Based Guideline for the management of high blood pressure in adults report from the panel members appointed to the eighth joint national committee (JNC 8)]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2014</year>
<volume>311</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>507-20</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fagard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Narkiewicz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Redon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zanchetti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Böhm]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2013 ESH/ESC Guidelines for the management of arterial hypertension]]></article-title>
<source><![CDATA[Eur Hear jou]]></source>
<year>2013</year>
<volume>34</volume>
<page-range>2159-219</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Guía de práctica clínica Hipertensión arterial primaria (HTA)]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Currier]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Lundgren]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Carr]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sabin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sax]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2008</year>
<volume>118</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>e19-35</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klein]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hurley]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Quesenberry]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sidney]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Do proteasa inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?]]></article-title>
<source><![CDATA[JAIDS]]></source>
<year>2002</year>
<volume>30</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>471-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverberg]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Leyden]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Horberg]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Chao]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Towner]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with acccess to care]]></article-title>
<source><![CDATA[J Acquir Inmune Defic Syndr]]></source>
<year>2014</year>
<volume>65</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>160-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serrano-villar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pe]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sainz]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Navas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hermida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Royuela]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a Low CD4 / CD8 ratio]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Triant]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hadigan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Grinspoon]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2007</year>
<volume>92</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2506-12</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freiberg]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Kuller]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Goetz]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Leaf]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Oursler]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV infection and the risk of acute myocardial infarction]]></article-title>
<source><![CDATA[JAMA Intern Med]]></source>
<year>2013</year>
<volume>173</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>614-22</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friis-Møller]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Worm]]></surname>
<given-names><![CDATA[S.W]]></given-names>
</name>
<name>
<surname><![CDATA[Sabin]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Class of antiretroviral drugs and the risk of myocardial infarction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>356</volume>
<page-range>1723-35</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iloeje]]></surname>
<given-names><![CDATA[UH]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Italien]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Mauskopf]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Holmberg]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Moorman]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients]]></article-title>
<source><![CDATA[HIV Med]]></source>
<year>2005</year>
<volume>6</volume>
<page-range>37-44</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friis-Møller]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Reiss]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Thie]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kirk]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Monforte]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2003</year>
<volume>17</volume>
<page-range>1179-93</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Savès]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chene]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ducimetière]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2003</year>
<volume>37</volume>
<page-range>292-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Joy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Keogh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hadigan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dietary fat intake and relationship to serum lipid levels among HIV-infected subjects with metabolic abnormalities in the era of HAART]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2007</year>
<volume>21</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1591-600</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mdodo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Frazier]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Dube]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Mattson]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Sutton]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Brooks]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cigarette smoking prevalence among adults with HIV compared with the General adult population in the United States cross-sectional surveys]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2015</year>
<volume>162</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>335-44</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
<name>
<surname><![CDATA[Helleberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[May]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Afzal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kronborg]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Larsen]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myocardial infarction among danish HIV- infected individuals: population-attributable fractions associated with smoking]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2015</year>
<volume>60</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1415-23</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crowell]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Gebo]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Blankson]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Korthuis]]></surname>
<given-names><![CDATA[PT]]></given-names>
</name>
<name>
<surname><![CDATA[Yehia]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Rutstein]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2015</year>
<volume>211</volume>
<page-range>1692-702</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Guía de práctica clínica (GPC) basada en la evidencia científica para la atención de la infección por VIH / Sida en adolescentes (con 13 años de edad o más) y adultos]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[D&#8217;Agostino]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Vasan]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Pencina]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Cobain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Massaro]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[General cardiovascular risk profile for use in primary care the framingham heart study]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2008</year>
<volume>117</volume>
<page-range>743-53</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vidal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pedrol]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del riesgo cardiovascular e intervención en los pacientes con VIH]]></article-title>
<source><![CDATA[Enferm Infecc Microbiol Clin]]></source>
<year>2009</year>
<volume>27</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>40-7</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Friis-Møller]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[El-sadr]]></surname>
<given-names><![CDATA[WM]]></given-names>
</name>
<name>
<surname><![CDATA[Reiss]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Monforte]]></surname>
<given-names><![CDATA[ADA]]></given-names>
</name>
<name>
<surname><![CDATA[Thiébaut]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study]]></article-title>
<source><![CDATA[HIV Med]]></source>
<year>2006</year>
<volume>7</volume>
<page-range>218-30</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Begovac]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dragovic]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Viskovic]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lukas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy]]></article-title>
<source><![CDATA[Croat Med J]]></source>
<year>2015</year>
<volume>56</volume>
<page-range>14-23</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Markowicz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Delforge]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Necsoi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wit]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk evaluation of HIV-positive patients in a case-control study: comparison of the D:A:D and Framingham equations]]></article-title>
<source><![CDATA[Journal of the International AIDS Society]]></source>
<year>2014</year>
<page-range>1-2</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nery]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Martelli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Alencar de Sousa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Falco]]></surname>
<given-names><![CDATA[MDO]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira A de]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons]]></article-title>
<source><![CDATA[Sci World J]]></source>
<year>2013</year>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pirs]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jug]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Er&#382;en]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[&#352;abovi&#263;]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Karner]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Poljak]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk assessment in HIV-infected male patients: a comparison of Framingham, SCORE, PROCAM and DAD risk equations]]></article-title>
<source><![CDATA[Acta dermatovenerologica]]></source>
<year>2014</year>
<volume>23</volume>
<page-range>43-7</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bartolomeu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ingles]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[de Oliveira]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bastos]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[de Campos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions]]></article-title>
<source><![CDATA[Int J Clin Pr]]></source>
<year>2010</year>
<volume>64</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>739-45</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Socio]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Parruti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Quirino]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ricci]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schillaci]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Adriani]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study]]></article-title>
<source><![CDATA[Br Infect Soc]]></source>
<year>2008</year>
<volume>57</volume>
<page-range>33-40</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thompson-Paul]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtenstein]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Armon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Palella]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Skarbinski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chmiel]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular disease risk prediction in the HIV outpatient study]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2016</year>
<volume>63</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1508-16</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chapel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Heiss]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Toole]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chambless]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Romm]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The atherosclerosis risk in comunities (ARIC) study: design and objetives]]></article-title>
<source><![CDATA[Am J Epidemiol]]></source>
<year>1989</year>
<volume>129</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>687-702</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fried]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Borhani]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Enright]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Furberg]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Gardin]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Kronmal]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The cardiovascular health study: design and rationale]]></article-title>
<source><![CDATA[Ann Epidemiol]]></source>
<year>1991</year>
<volume>1</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>263-76</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dawber]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Kannel]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Lyell]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An approach to longitudinal studies in a community: the framingham study]]></article-title>
<source><![CDATA[Ann N Y Acad Sci]]></source>
<year>1963</year>
<volume>107</volume>
<page-range>539-56</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kannel]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Feinleib]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McNamara]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Garrison]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Castelli]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An investigation of coronary heart disease in families. The Framingham offspring study]]></article-title>
<source><![CDATA[Am J Epidemiol]]></source>
<year>1979</year>
<volume>110</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>281-90</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feinstein]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Nance]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Drozd]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Ning]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Delaney]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Heckbert]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus a study by the centers for AIDS research network of integrated clinical systems]]></article-title>
<source><![CDATA[JAMA Cardiol]]></source>
<year>2016</year>
<page-range>E1-8</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crane]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Heckbert]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Drozd]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Budoff]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Delaney]]></surname>
<given-names><![CDATA[JAC]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practice of epidemiology lessons learned from the design and implementation of myocardial infarction adjudication tailored for HIV clinical cohorts]]></article-title>
<source><![CDATA[Am J E pidemiol]]></source>
<year>2014</year>
<volume>179</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>996-1005</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buchacz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Moorman]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Richardson]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Holmberg]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2008</year>
<volume>22</volume>
<page-range>1345-56</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buchacz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Baker]]></surname>
<given-names><![CDATA[RK]]></given-names>
</name>
<name>
<surname><![CDATA[Palella]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chmiel]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtenstein]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Novak]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AIDS-defining opportunistic illnesses in US patients, 1994 - 2007: a cohort study]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2010</year>
<volume>24</volume>
<page-range>1549-59</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rondón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validación de los modelos de predicción de Framingham y PROCAM como estimadores del riesgo cardiovascular en una población colombiana]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2014</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>202-12</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friis-Møller]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sabin]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Arminio Monforte]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[El-sadr]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination antiretroviral therapy and the risk of myocardial infarction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>349</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>1993-2003</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masiá-canuto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal-morell]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez-rodero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alteraciones lipídicas y riesgo cardiovascular asociado a la terapia antirretroviral]]></article-title>
<source><![CDATA[Enferm Infecc Microbiol Clin]]></source>
<year>2006</year>
<volume>24</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>637-48</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Joyce]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bendavid]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Olshen]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Hlatky]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2015</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>445-52</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bavinger]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bendavid]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Niehaus]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Olshen]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Olkin]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sundaram]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Andraca-Carrera]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Miele]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kornegay]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Soukup]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis]]></article-title>
<source><![CDATA[J Acquir Inmune Defic Syndr]]></source>
<year>2012</year>
<volume>61</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>441-7</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lake]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Currier]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic disease in HIV infection]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2013</year>
<volume>13</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>964-75</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quercia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-boosted Darunavir-based regimens over 48 weeks]]></article-title>
<source><![CDATA[Clin Drug Investig]]></source>
<year>2015</year>
<volume>35</volume>
<page-range>211-9</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Myerson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lipid management in human immunodeficiency virus]]></article-title>
<source><![CDATA[Endocrinol Metab Clin NA]]></source>
<year>2016</year>
<volume>45</volume>
<page-range>141-69</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="">
<collab>Grupo de expertos del grupo de estudio sobre alteraciones metabólicas</collab>
<collab>S del plan nacional sobre el sida (SPNS)</collab>
<collab>grupo de estudio de sida</collab>
<source><![CDATA[Documento de consenso sobre alteraciones metabólicas y riesgo cardiovascular en pacientes con infección por el VIH (Actualización febrero 2017)]]></source>
<year>2017</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="">
<collab>AIDSinfo</collab>
<source><![CDATA[Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Developed by the DHHS Panel on Antiretroviral Guidelines for Adults]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calza]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Manfredi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chiodo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART]]></article-title>
<source><![CDATA[Infection]]></source>
<year>2002</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-31</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="">
<collab>Liverpool HIV Pharmacology Group</collab>
<source><![CDATA[(LHPG) S of BS at the U of L]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feeney]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Mallon]]></surname>
<given-names><![CDATA[PWG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV and HAART-associated dyslipidemia]]></article-title>
<source><![CDATA[Open Cardiovasc Med J]]></source>
<year>2011</year>
<volume>5</volume>
<page-range>49-63</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Arnaiz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Podzamczer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dalmau]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ribera]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Domingo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Substitution of Nevirapine, Efavirenz, or Abacavir for protease inhibitors in patients with human immunodeficiency virus infection]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>349</volume>
<page-range>1036-46</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Palella]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Tebas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[]]></source>
<year>2012</year>
<conf-name><![CDATA[ SPIRIT study: switching boosted PI to Rilpivirine in combination with Truvada as an STR adults; 11th international congress on drug therapy in HIV infection]]></conf-name>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Albuquerque]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Pitch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gatell]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abacavir/ Lamivudine versus Tenofovir/Emtricitabine in virologically suppressed patients switching from Ritonavir- boosted protease inhibitors to raltegravir]]></article-title>
<source><![CDATA[AIDS Res Hum Retroviruses]]></source>
<year>2013</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>3-6</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arribas]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Pialoux]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gathe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Di]]></surname>
<given-names><![CDATA[Perri G]]></given-names>
</name>
<name>
<surname><![CDATA[Reynes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tebas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV ( STRATEGY-PI ): 48 week results]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2014</year>
<volume>14</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Squires]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Dejesus]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ward]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Suppression in HIV-infected patients simplified to unboosted Atazanavir/ Abacavir/Lamivudine]]></article-title>
<source><![CDATA[HIV Clin Trials]]></source>
<year>2012</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>233-44</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palella]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tebas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gazzard]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ruane]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Van]]></surname>
<given-names><![CDATA[Lunzen J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Simplification to rilpivirine/emtricitabine/ tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2014</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>335-44</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gatell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Salmon-ceron]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lazzarin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Van]]></surname>
<given-names><![CDATA[Wijngaerden E]]></given-names>
</name>
<name>
<surname><![CDATA[Antunes]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Leen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of Atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a Stable, boosted or unboosted protease inhibitor treatment regimen: The SWAN study (AI424-097) 48-week results]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2007</year>
<volume>44</volume>
<page-range>1484- 92</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bánhegyi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Katlama]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Arns]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rachlis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Workman]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Week 96 efficacy, virology and safety of Darunavir/r versus Lopinavir/r in treatment-experienced patients in TITAN]]></article-title>
<source><![CDATA[Curr HIV Res]]></source>
<year>2012</year>
<volume>10</volume>
<page-range>171-81</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Calmy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Delhumeau]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mercier]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cavassini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mello]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2011</year>
<volume>25</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1481-7</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dejesus]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Brinson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yale]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety 48 weeks after switching from Efavirenz to Rilpivirine using Emtricitabine/Tenofovir disoproxil fumarate-based single-tablet regimens]]></article-title>
<source><![CDATA[HIV Clin Trials]]></source>
<year>2013</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>216-23</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moyle]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shahmanesh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ewan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Orkin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kingston]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized comparative trial of continued Zidovudine/Lamivudine or replacement with Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-treated HIV-1 - infected individuals]]></article-title>
<source><![CDATA[J Acquir Inmune Defic Syndr]]></source>
<year>2009</year>
<volume>51</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>562-8</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ribera]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Larrousse]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Curran]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Negredo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Clotet]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Estrada]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of switching from zidovudine/ lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study]]></article-title>
<source><![CDATA[HIV Med]]></source>
<year>2013</year>
<volume>14</volume>
<page-range>327-36</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moyle]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sabin]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Cartledge]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wilkins]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Churchill]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hay]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2006</year>
<page-range>2043-50</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Carr]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ringland]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Amin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Emery]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2004</year>
<volume>18</volume>
<page-range>1029-36</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Behrens]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maserati]]></surname>
<given-names><![CDATA[RRA]]></given-names>
</name>
</person-group>
<source><![CDATA[Switching from kivexa (ABC/3TC)+Kaletra (LPV/r) reduces high cholesterol: results of a 12 week randomized, controlled study (ROCKETT II)]]></source>
<year></year>
<conf-name><![CDATA[ Program and abstracts of the XVIII International AIDS Conference]]></conf-name>
<conf-loc>Vienna, Austria </conf-loc>
</nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dejesus]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bredeek]]></surname>
<given-names><![CDATA[UF]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Khanlou]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Logue]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HIV/AIDS SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/Tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regime]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2013</year>
<volume>56</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1637-45</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moyle]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Orkin C]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
</person-group>
<source><![CDATA[Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) + Efavirenz improves lipid levels towards NCEP recommendations: results of a 24-week randomized study]]></source>
<year></year>
<conf-name><![CDATA[ Program and abstracts of the XVIII International AIDS Conference]]></conf-name>
<conf-loc>Vienna, Austria </conf-loc>
</nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kassi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pervanidou]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kaltsas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Chrousos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic syndrome: definitions and controversies]]></article-title>
<source><![CDATA[BMC Med]]></source>
<year>2011</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>48</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alberti]]></surname>
<given-names><![CDATA[KGMM]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmet]]></surname>
<given-names><![CDATA[PZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Definition, diagnosis and classification of diabetes mellitus and its complications part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation]]></article-title>
<source><![CDATA[Diabet Med]]></source>
<year>1998</year>
<volume>15</volume>
<page-range>539-53</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grundy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Denke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III).]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2002</year>
<volume>106</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>3143-421</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alberti]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The metabolic syndrome - a new worldwide definition]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>366</volume>
<numero>9491</numero>
<issue>9491</issue>
<page-range>1059-62</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grundy]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Cleeman]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Donato]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Eckel]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Franklin]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of the metabolic syndrome]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2005</year>
<volume>112</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>2735-52</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alberti]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Eckel]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Grundy]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Zimmet]]></surname>
<given-names><![CDATA[PZ]]></given-names>
</name>
<name>
<surname><![CDATA[Cleeman]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Donato]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Harmonizing the metabolic syndrome. A joint interim statement of the international diabetes federation Task Force on epidemiology and prevention; national heart, lung, and blood institute; American Heart Association; World Heart Federation; International]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2009</year>
<volume>120</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1640-5</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jericó]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Knobel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Montero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ordoñez-Llanos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guellar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gimeno]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic syndrome among HIV-infected patients]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2005</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>144-9</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mondy]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Grubb]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tong]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Seyfried]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Powderly]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2007</year>
<volume>44</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>726-34</page-range></nlm-citation>
</ref>
<ref id="B90">
<label>90</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Palaniappan]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Heshka]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carnethon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Heymsfield]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988-1994]]></article-title>
<source><![CDATA[Arch Intern Med]]></source>
<year>2003</year>
<volume>163</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>427-36</page-range></nlm-citation>
</ref>
<ref id="B91">
<label>91</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samaras]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Wand]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Emery]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Carr]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international diabetes foundation and adult treatment panel III criteria]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2007</year>
<volume>30</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>113-9</page-range></nlm-citation>
</ref>
<ref id="B92">
<label>92</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobson]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Spiegelman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Skinner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gorbach]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey)]]></article-title>
<source><![CDATA[J Acquir Inmune Defic Syndr]]></source>
<year>2006</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>458-66</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wand]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Calmy]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carey]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Samaras]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Carr]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2010</year>
<volume>21</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>2445-53</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Obesity: preventing and managing the global epidemic]]></source>
<year>2000</year>
</nlm-citation>
</ref>
<ref id="B95">
<label>95</label><nlm-citation citation-type="">
<collab>National Institutes of Health</collab>
<source><![CDATA[Guide identification, evaluation , and treatment of overweight and obesity in adults]]></source>
<year>2000</year>
</nlm-citation>
</ref>
<ref id="B96">
<label>96</label><nlm-citation citation-type="">
<collab>Health Canada</collab>
<source><![CDATA[Canadian guidelines for body weight classification in adults]]></source>
<year>2003</year>
<publisher-loc><![CDATA[Otawa ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B97">
<label>97</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[McAlister]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rabkin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Padwal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 2006 Canadian hypertension education program recommendations for the management of hypertension: Part II -Therapy]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2006</year>
<volume>22</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>583-93</page-range></nlm-citation>
</ref>
<ref id="B98">
<label>98</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graham]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Atar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Borch-Johnsen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Boysen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Burell]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cifkova]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European guidelines on cardiovascular disease prevention in clinical practice: Executive summary]]></article-title>
<source><![CDATA[Atherosclerosis]]></source>
<year>2007</year>
<volume>194</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-45</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>99</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oka]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yagi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tanii]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Miyamoto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reassessment of the cutoff values of waist circumference and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome]]></article-title>
<source><![CDATA[Diabetes Res Clin Pr]]></source>
<year>2008</year>
<volume>79</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>474-81</page-range></nlm-citation>
</ref>
<ref id="B100">
<label>100</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Examination committee of criteria for &#8220;Obesity Disease&#8221; in Japan. New Criteria for &#8220;Obesity Disease&#8221; in Japan]]></article-title>
<source><![CDATA[Circ J]]></source>
<year>2002</year>
<volume>66</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>987-92</page-range></nlm-citation>
</ref>
<ref id="B101">
<label>101</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lekakis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ikonomidis]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Palios]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tsiodras]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Karatzis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Poulakou]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of highly active antiretroviral therapy with increased arterial stiffness in patients infected with human immunodeficiency virus]]></article-title>
<source><![CDATA[Am J Hypertens]]></source>
<year>2009</year>
<volume>22</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>828-34</page-range></nlm-citation>
</ref>
<ref id="B102">
<label>102</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Miralles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Podzamczer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Considerations on the increase in blood pressure among antiretroviral-naive patients starting HAART]]></article-title>
<source><![CDATA[AIDS]]></source>
<year>2007</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>384-6</page-range></nlm-citation>
</ref>
<ref id="B103">
<label>103</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bernardino]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zamora]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Montes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García-Puig]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arribas]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipertensión arterial, infección por el virus de la inmunodeficiencia humana y tratamiento antirretrovírico de gran actividad]]></article-title>
<source><![CDATA[Enferm Infecc Microbiol Clin]]></source>
<year>2010</year>
<volume>28</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>32-7</page-range></nlm-citation>
</ref>
<ref id="B104">
<label>104</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Jaramillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Matijasevic]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rendón]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio poblacional de factores de riesgo cardiovascular relacionados con el estilo de vida, hallazgos electrocardiográficos y medicación actual de pacientes valorados por el servicio de Cardiología]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2012</year>
<volume>19</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>61-71</page-range></nlm-citation>
</ref>
<ref id="B105">
<label>105</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Día mundial de la salud 2013: Mida su tensión arterial, reduzca su riesgo]]></source>
<year>2003</year>
</nlm-citation>
</ref>
<ref id="B106">
<label>106</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pickering]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Shimbo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Haas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ambulatory blood-pressure monitoring]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2006</year>
<volume>354</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>2368-74</page-range></nlm-citation>
</ref>
<ref id="B107">
<label>107</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Peer]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kengne]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Burden, determinants, and pharmacological management of hypertension in HIV-positive patients and populations: A systematic narrative review]]></article-title>
<source><![CDATA[AIDS Rev]]></source>
<year>2015</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>83-95</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
